Acute and long-term treatment of mania by Vieta, Eduard & Sanchez-Moreno, Jose
anic-depressive illness,currently known as bipo-
lar disorder,is a common,severe,long-term condition.The
World Health Organization reported in 2001 that bipolar
disorder was the fifth cause of life years lived with a dis-
ability among young adults.
1 It is characterized by the
recurrence of mania, depression, or mixed episodes.
2
Mania is the most characteristic phase of bipolar disorder,
and a major cause of disability, stigma, and cognitive
impairment.
3,4 Lithium is the traditional treatment option,
but the majority of patients do not respond to lithium
monotherapy,and other drugs have been introduced in
the past decades, such as the anticonvulsants valproate
and carbamazepine.Other newer anticonvulsants,which
have failed to prove their efficacy in mania,have not been
used successfully.
5Antipsychotics are established as the
main treatment for schizophrenia,and have been tradi-
tionally used in mania,but recently a growing number of
trials have turned them into a broader therapeutic option
for bipolar disorder,as both alternative and adjunct to tra-
ditional mood stabilizers.
6,7 Second-generation antipsy-
chotics have been extensively studied in mania,but there
is also increasing evidence of the efficacy of at least some
of them in the treatment of bipolar depression and main-
tenance treatment of bipolar disorder. Moreover, sec-
ondary analysis from controlled trials suggest that some
antipsychotics may be helpful in the treatment of mixed
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The treatment of mania starts with a correct diagnosis and
elementary measures to prevent risks for the patient, rel-
atives, and others. Sometimes, compulsory admission and
treatment may be required for a few days. Patients with
psychotic or mixed mania may be more difficult to treat.
At the present time, there is solid evidence supporting the
use of lithium, the anticonvulsants valproate and carba-
mazepine, and the antipsychotics chlorpromazine,
haloperidol, risperidone, olanzapine, quetiapine, ziprasi-
done, aripiprazole, and asenapine in acute mania, and
some evidence supporting the use of clozapine or elec-
troconvulsive therapy in treatment-refractory cases.
However, in clinical practice, combination therapy is the
rule rather than the exception. The treatment of acute
mania deserves a long-term view, and the evidence base
for some treatments may be stronger than for others.
When taking decisions about treatment, tolerability
should also be a major concern, as differences in safety
and tolerability may exceed differences in efficacy for
most compounds. Psychoeducation of patients and care-
givers is a powerful tool that should be used in combina-
tion with medication for optimal long-term outcome.
Functional recovery should be the ultimate goal.    
© 2008, LLS SAS Dialogues Clin Neurosci. 2008;10:165-179.states and rapid cycling.In clinical reality,as demonstrated
in large naturalistic studies,the majority of patients with
acute mania are treated with combinations of the drugs
mentioned above,and even benzodiazepines as adjuvant
treatment.
8As an alternative option to lithium,anticon-
vulsants,and antipsychotics,or their combination,elec-
troconvulsive therapy is supported mainly by experience
and some limited evidence.
9,10 The treatment of milder
forms of mania and hypomania has clearly been insuffi-
ciently studied,although it is generally assumed that what
works for mania should work for hypomania as well;how-
ever, clinical decisions are generally made on a
benefit:risk ratio framework,and therefore more head-
to-head studies and specific trials in this subpopulation
are needed.Psychotic mania has been better studied,and
most trial reports provide separate analysis for psychotic
versus nonpsychotic patients. Finally, mixed mania has
also been studied in some trials,and may respond better
to valproate,atypical antipsychotics—or a combination of
the two—than to other traditional therapies,
11 but still
remains a challenge, especially due to the high risk of
switch to depression.
12
Management of acute mania: first steps
The goals of treatment of an acute manic or mixed
episode are to alleviate symptoms and allow a return to
usual levels of psychosocial functioning.Achieving rapid
control of agitation,aggression,and impulsivity is partic-
ularly important to ensure the safety of patients and
those around them,and to allow the establishment of a
therapeutic alliance.Sometimes,compulsory hospitaliza-
tion is needed to start effective treatment.
Although diagnostic criteria allow bipolar mood
episodes to be defined as hypomanic, manic, or mixed,
it can be difficult to reliably discriminate between them.
The degree or mood elevation per se is not the decisive
factor in choosing among the three diagnoses; instead,
the degree of impairment and behavioral disturbance,
as evidenced by aggression, agitation, psychosis, poor
judgment,and social or occupational dysfunction,is the
usual precipitant of clinical attention and hence the pri-
mary target of intervention. In practical terms, there-
fore, bipolar I patients presenting with a hypomanic,
manic,or mixed episode can usually be managed with a
common “acute mood elevation” strategy. However,
even if the split between acute treatment and long-term
treatment makes sense from an operational perspective,
in the last few years it has come clear that the best
approach to the treatment of bipolar disorder is an inte-
grative management approach,dealing with the urgent
and acute issues while keeping perspective on the long-
term ones and functional outcome. For this reason, the
treatment of mania must always take into account the
long-term issues, including not only the cross-sectional
assessment but also the predominant polarity of
episodes,
13 and the general principles as specified in the
decalogue for the management of bipolar disorder,
14
shown in Table I.
Pharmacological treatment of acute mania
The most widely used medications in the acute setting
are lithium, some anticonvulsants (valproate, carba-
mazepine), standard antipsychotics (eg, haloperidol,
chlorpromazine),atypical antipsychotics (eg,quetiapine,
olanzapine,risperidone,ziprasidone,aripiprazole,cloza-
pine),and benzodiazepines (eg,lorazepam,clonazepam).
The choice of initial treatment is influenced by the
patient’s current and prior medication history,the need
for rapid resolution of agitation and aggression,the char-
acteristics of the manic episode,and the presence of rapid
cycling,as well as the patient’s own willingness to accept
particular therapies and routes of administration.
Whenever possible,oral therapy should be offered first,
but intramuscular injections are an alternative if oral
therapy cannot be reliably administered.
The published consensus,clinical guidelines,and treat-
ment algorithms show some differences in their recom-
mendations for the first- and second-line treatment of
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1. To ensure the safety of the patient and others
2. To treat and reduce the severity of acute mood episodes when 
they occur
3. To treat psychotic symptoms when they occur
4. To avoid cycling from one episode to another
5. To prevent suicidal behavior
6. To reduce the frequency of mood episodes
7. To treat subthreshold symptoms
8. To treat comorbidities, overall health, and cognitive problems
9. To increase the patients’ and caregivers’ knowledge about the 
disorder and enhance treatment adherence
10. To help the patient function as effectively as possible between 
episodes
Table I. The decalogue of goals for intervention in bipolar disorder.
14acute mania.
15Although the majority support the use of
monotherapy with lithium,valproate,and in some cases
olanzapine and other antipsychotics in mild-to-moderate
mania,there is increasing recognition that a significant
number of patients will end up receiving two or more
drugs.
Lithium 
Lithium has been used in the treatment of acute bipolar
mania for over 50 years,and has demonstrated superior-
ity over placebo in several controlled clinical trials.
16 In
these studies,the percentage of patients showing at least
moderate improvement after 2 to 3 weeks of treatment
ranged from 40% to 80%.Lithium appears to be most
effective in patients with classic (euphoric) mania,while
response rates are relatively poor in mixed states or rapid
cycling.
17
Drawbacks of lithium therapy include its narrow thera-
peutic index (recommended plasma level 0.8 to 1.2
mmol/L),poor tolerability,especially at higher doses,and
risk of “rebound mania”on withdrawal.
18 Common side
effects of lithium are tremor,polydipsia,polyuria,and,in
the long term,hypothyroidism.Despite these shortcom-
ings,lithium retains a role as a first-line treatment and is
widely seen as the gold-standard comparator for newer
agents,not to say that it may have antisuicidal effects.
19,20
Lithium also been evaluated in relation to other anti-
manic agents.Head-to-head comparisons with antipsy-
chotic drugs (usually chlorpromazine) have generally
found lithium to be superior in terms of overall improve-
ment in symptoms,mood,and ideation,but worse with
respect to motor hyperactivity and onset of action.
Lithium was as efficacious as quetiapine in a 12-week,
randomized,double-blind trial
21 In a three-arm random-
ized study comparing placebo, lithium, and valproate,
lithium and valproate were similarly effective in improv-
ing manic symptoms.
22
Randomized comparisons of a mood stabilizer (lithium
or valproate), alone or in combination with antipsy-
chotics,generally found that the combinations were supe-
rior to monotherapy for the rapid control of manic symp-
toms.
23 By contrast,two double-blind studies
24,25 failed to
show superiority of lithium plus an antipsychotic
(haloperidol or pimozide) over the antipsychotic alone
in the treatment of acute mania.Lithium has also been
found to be well tolerated in combination with either
antipsychotics or anticonvulsants.
26
Anticonvulsants
Valproate
Several galenic forms of valproic acid, the final active
product,are available across the world,and have been
used since the 1960s in Europe for the treatment of bipo-
lar disorder. Subsequently, two double-blind studies
found valproate to be superior to placebo and as effec-
tive as lithium in the treatment of acute mania.
22,27 A
pooled analysis of these studies indicated that 54% of
patients treated with valproate experienced a reduction
of at least 50% in manic symptomatology.Unlike lithium,
valproate has a rapid onset of action,producing signifi-
cant clinical improvements within 1 week,and is equally
effective in treating mixed and classic mania.
17Valproate
may not be as efficacious as antipsychotics such as olan-
zapine
28,29), but is generally better tolerated.
30 An
extended-release form of valproate is also available and
proven to be effective in mania.
31 Some guidelines,such
as the United Kingdom NICE guidelines,advise against
the use of valproate in women of childbearing age,due
to the high frequency of unplanned pregnancies in
women with and even without bipolar disorder,and the
relatively high teratogenicity of the compound,but this
may be going too far, and could prove impractical.
32
Other potential acute side effects of valproate are weight
gain and hair loss.
Carbamazepine
Since its introduction into psychiatric treatment,
33 carba-
mazepine has been evaluated in several randomized con-
trolled trials, but most had methodological limitations
such as small patient numbers or concomitant treatment.
A placebo-controlled study in which patients were not
receiving adjunctive medication found that 63% of car-
bamazepine-treated patients displayed significant
improvements in manic,depressive,and psychotic symp-
toms,an effect that was lost on switching to placebo.
34The
statistical significance of the treatment effect was not
given,however.
Recently, two randomized, double-blind studies have
assessed an extended-release formulation of carba-
mazepine as monotherapy for the acute treatment of
manic or mixed episodes.
35,36 Both trials found carba-
mazepine to be significantly superior to placebo; side
effects included dizziness,somnolence,nausea,vomiting,
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167ataxia,blurred vision,dyspepsia,dry mouth,pruritus,and
speech disorder.
Two studies have compared carbamazepine with lithium
in a randomized, controlled manner, with conflicting
results.One found that lithium was superior,
37 while the
other found the drugs to be equivalent.
38 Two studies
comparing carbamazepine with chlorpromazine have
found no differences between the drugs.A double-blind
study found that carbamazepine in combination with
lithium was as effective as lithium plus haloperidol in the
treatment of acute mania.
39
In all these studies, the antimanic effect of carba-
mazepine became evident after 1 to 2 weeks.
Uncontrolled studies have suggested a role for carba-
mazepine in rapid cycling and mixed states, but these
require confirmation.A potentially life-threatening side
effect of carbamazepine may be the Stevens-Johnson
syndrome and related dermatologic effects.
Other anticonvulsants
Newer anticonvulsants such as lamotrigine,gabapentin,
and topiramate have failed to demonstrate superiority
over placebo in randomized controlled studies of bipolar
mania,and there is practically no evidence to support the
use of tiagabine,levetirazetam,pregabalin,or zonisamide.
There is some limited evidence that phenytoin may pos-
sess antimanic effects.
40 Oxcarbazepine,structurally sim-
ilar to carbamazepine,may possess antimanic effects,
41
but licarbazepine,its main active metabolite,failed in at
least one placebo-controlled trial. Clearly, not all anti-
convulsants are antimanics.
Antipsychotics
Antipsychotics have been used since their introduction
in clinical practice for the treatment of acute mania.For
years, though, the evidence base for this practice was
extremely limited. Now, the US Food and Drug
Administration (FDA) has already approved six antipsy-
chotics for the treatment of acute mania:chlorpromazine,
olanzapine,risperidone,quetiapine,ziprasidone,and arip-
iprazole.Current criteria for FDA approval include two
multicenter, randomized, double-blind, placebo-con-
trolled trials with adequate sample sizes supporting the
safety and efficacy of these agents.These drugs are also
approved for the treatment of mania in most European
countries and in most countries worldwide.
Chlorpromazine
Chlorpromazine is a first-generation antipsychotic that
has been studied only in one small,placebo-controlled
trial
42 and a few comparative,randomized studies,versus
lithium,haloperidol,and pimozide.
43-45The main problems
related to chlorpromazine use are extrapyramidal symp-
toms,tardive dyskinesia (long-term),and hepatotoxicity.
Haloperidol
Only recently have the results of placebo-controlled tri-
als with this drug become available.Studies conducted in
the 1970s already suggested that it could be efficacious
in mania,and recent trials have shown that it has strong
antimanic properties,
46,47 but it may also carry important
side effects such as extrapyramidal symptoms and tardive
dyskinesia, among others. It is particularly relevant to
mention that, although haloperidol seemed to have a
faster onset of antimanic action than other antipsychotics
in several controlled trials,it also significantly reduced
the time until first depressive recurrence in one of them.
48
Haloperidol has been compared as monotherapy with
placebo,risperidone,olanzapine,quetiapine,ziprasidone,
and aripiprazole,and as an add-on to placebo and risperi-
done.
46-52
Clozapine
Clozapine is the prototype of an atypical antipsychotic,
but has not been as widely studied as the others in its
class, due to the risks of seizures and agranulocytosis.
Thus,to date we have no double-blind clinical trials on
clozapine in acute mania.Nevertheless,there are open
studies with a few patients showing that clozapine could
be effective as a treatment for dysphoric mania.
53Twenty-
seven patients with acute mania were recruited for an
open study in which they were divided into two groups:
15 would take clozapine,the remaining 12 taking chlor-
promazine.The clozapine-treated group achieved signif-
icantly greater reduction in Young Mania Rating Scale
(YMRS) scores at the second week but not at the third
week,this suggesting a probably faster improvement of
mania through clozapine treatment.
54
A prospective trial was set for 25 acutely manic patients
with either bipolar disorder (n=10) or schizoaffective dis-
order-bipolar subtype (n=15) First-line treatments
(lithium,anticonvulsants) and antipsychotics were not
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168effective, produced intolerable side effects, or both.
Seventy-two percent improved on the YMRS and 32%
improved on the Brief Psychiatric Rating Scale (BPRS).
Bipolar and nonrapid cycling patients had significantly
greater improvement as compared with schizoaffective
patients and rapid cyclers respectively.According to this
trial,clozapine could be an effective therapy for treat-
ment-resistant bipolar and schizoaffective mania.
55
Besides the potential risk for agranulocytosis and
seizures,other potential side effects of acute use of cloza-
pine include clinically significant weight gain and sialor-
rhea.
Risperidone
There are several studies on the antimanic effect of
risperidone as monotherapy.A 3-week,multicenter,dou-
ble-blind, placebo controlled trial was carried out
recently in 259 patients.
56 Risperidone significantly
improved both YMRS and CGI (Clinical Global
Impression).Improvement was significant from the third
day of treatment onwards (P<0.01 vs placebo).Another
3-week trial recruited 290 bipolar I patients:those ran-
domized to risperidone improved significantly from the
third day compared with placebo, and made quicker
breakthroughs than those randomized to placebo.
Response to treatment was defined as at least 50%
decrease in YMRS score: it was achieved in 73% and
36% of those randomized to risperidone and placebo
respectively (P<0.001).The main downsides of risperi-
done were the risk of dose-related extrapyramidal symp-
toms and hyperprolactinemia.
57
Smulevich et al designed a 3-week controlled trial in
which manic patients would receive risperidone,
haloperidol,or placebo followed by a double-blind trial
of risperidone and haloperidol.The conclusion was that
risperidone and haloperidol were similarly effective in
the treatment of acute mania,this being significant com-
pared with placebo. Risperidone was reported to be
safer,and efficacy was maintained over the long term.
46
Risperidone has also been studied as adjunct treatment
to lithium,valproate semisodium,or carbamazepine.A
3-week,double-blind,randomized,controlled trial stud-
ied mood stabilizers plus risperidone or placebo in the
treatment of acute mania
58At the study end point YMRS
scores improved by –14.5 and –10.3 in the risperidone
and placebo groups respectively,not reaching statistical
significance (P<0.089),probably because of the effect of
carbamazepine on risperidone’s plasmatic levels through
hepatic enzyme induction.When risperidone plus lithium
or valproate semisodium were compared with placebo
plus lithium or valproate semisodium, YMRS scores
improved by –15.2 and –9.8,this being statistically sig-
nificant (P<0.047) In another trial a double-blind,
placebo-controlled comparison was made between
haloperidol,risperidone,or placebo added to a mood sta-
bilizer in patients with acute mania.
48 Both haloperidol
and risperidone achieved significantly greater reductions
in YMRS scores than the placebo group. It should be
noted that,despite the titles of the articles,both studies
included patients with mixed states.
Some authors suggested that risperidone could exacer-
bate or induce mania,presumably through antidepres-
sant effects
59 but further trials
60-62 confirmed that risk to
be very low.
Olanzapine
Olanzapine is the most studied of all the atypical antipsy-
chotics.
63 It has been studied as monotherapy treatment
for acute mania with positive results in several trials.Two
randomized,double-blind,placebo-controlled trials were
carried out: over 3
64 or 4
65 weeks, patients received
placebo or olanzapine.Response was again defined as at
least 50% improvement on YMRS score.In the first trial
48.6% of the olanzapine group and 24.2% of the placebo
group responded. In the second trial the percentages
increased to 64.8% and 42.9%.
A 12-week, double-blind comparison of olanzapine vs
haloperidol in the treatment of acute mania was pub-
lished in 2003.
48 Olanzapine failed to best haloperidol in
improving manic symptoms,but patients randomized to
haloperidol switched more rapidly to depression.
Olanzapine has also been compared with lithium and
divalproex in the treatment of mania.In a 4-week dou-
ble-blind trial,manic patients were randomized to olan-
zapine or lithium.Olanzapine was at least as effective as
lithium.
66A 3-week,randomized,double-blind trial com-
pared olanzapine with divalproex for the treatment of
manic or mixed episodes. Olanzapine-treated patients
had a higher decrease in YMRS scores than divalproex-
treated ones. Percentages of response (reduction of at
least 50% of the YMRS score) were 54.4% and 42.3%,
respectively.Dry mouth,weight gain,increased appetite,
and somnolence were more reported amongst the olan-
zapine patients,while nausea was more frequent in the
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169divalproex group.
28A randomized 12-week,double-blind
multicenter study compared both drugs,finding no sig-
nificant difference in efficacy between treatment groups.
Divalproex was associated with fewer adverse events
(including weight gain) than olanzapine.
30
A 6-week double-blind,randomized,placebo-controlled
trial was developed in order to compare combinations of
olanzapine plus lithium or valproate vs lithium or val-
proate alone.
67 The patients included suffered from an
acute manic or mixed bipolar episode,and were inade-
quate responders after 2 weeks of mood stabilizer alone.
Rates of improvement on YMRS scores were signifi-
cantly higher with combined treatment (67.7% vs 44.7%;
P<0.001) Improvement itself was higher too (-13.11 vs
-9.10;P=0.003).Those patients with mixed episodes pre-
senting moderate-to-severe depressive symptoms (DSM-
IV criteria for mixed episode;Hamilton Rating Scale for
Depression [HAMD] at least 20 at baseline),olanzapine
cotherapy improved HAMD scores to a greater extent
(10.31 points compared with 1.57 for mood stabilizer
alone;P<0.001).A recent trial failed to prove any further
benefit of the addition of olanzapine to carbamazepine
as opposed to carbamazepine alone.
68 One of the major
drawbacks of olanzapine is its weight gain liability,and
some tendency to increase glucose and lipid levels in
blood in the longer term.
Quetiapine
Three hundred and two patients with an acute manic
episode participated in a double-blind trial being ran-
domized to quetiapine,haloperidol,or placebo.At day 21
quetiapine had improved YMRS score (-12.29 vs -8.32
for placebo;P< 0.01) At day 84 difference from placebo
was also significant (-17.52 vs -9.48;P<0.001) At day 21
haloperidol-treated patients were significantly improved
(-15.71;P<0.001) as well as at Day 84 (-18.92;P<0.001).
47
Quetiapine,lithium,and placebo were randomly adminis-
tered to manic patients in a double-blind trial.This second-
generation antipsychotic was significantly superior to
placebo in reducing YMRS score and similar to lithium.
21
A combined analysis of these two trials supported queti-
apine as fast-acting and well tolerated in the treatment of
mania. Somnolence and hypotension were the main
adverse events,which also included some weight gain.
69
Two randomized,double-blind,placebo-controlled stud-
ies were designed to evaluate the efficacy and tolerabil-
ity of quetiapine when adjuncted to lithium or divalproex
in the treatment of acute mania.In one of them,the que-
tiapine-mood stabilizer group had a significantly greater
reduction in the YMRS score when compared with the
placebo-mood stabilizer group (-13.76 vs -9.93;P=0.021).
The response rate (reduction of at least 50% of the YMRS
score) was significantly higher in the quetiapine-mood sta-
bilizer group than in the placebo-mood stabilizer group
(54.3% vs 32.6%; P=0.005) Clinical remission (YMRS
score below 12) was also significantly higher (45.7% vs
25.8%;P=0.007).
70 In the second study,quetiapine did not
separate from placebo at study end point.
71 One of the
commonest side effects of quetiapine is sedation.
Ziprasidone
A 3-week double-blind trial randomized 210 patients with
a manic or mixed episode either to ziprasidone or to
placebo
72The study evaluated the efficacy and tolerability
of ziprasidone compared with placebo.Patients on ziprasi-
done improved relative to baseline and placebo on all pri-
mary and most secondary efficacy measures at end point.
Measures included were Clinical Global Impression (CGI,
severity and improvement), Positive and Negative
Syndrome Scale (PANSS), and Schedule for Affective
Disorders and Schizophrenia-Change Mania Rating Scale
(SADS-C MRS).Responders to treatment (at least 50%
improvement on MRS) were 50% of the ziprasidone group
and 35% of the placebo group (P<0.05).Another 3-week
trial was newly positive for ziprasidone.Somnolence and
extrapyramidal symptoms were the most reported adverse
events.
73A third monotherapy placebo-controlled trial also
had a haloperidol arm,and showed significant superiority
over placebo but lower efficacy versus haloperidol (up to
30 mg/day) at the 3-week and 12-week end points.
52,74
Two hundred and five bipolar patients receiving lithium
were part of a double-blind trial that studied ziprasidone
as add-on treatment over 3 weeks. This trial failed to
yield positive results.Somnolence,extrapyramidal symp-
toms,dizziness,and agitation were more frequent in the
group receiving ziprasidone and lithium.
75 Another
potential side effect of the drug is activation (some sort
of akathisia vs anxiety and restlessness).Further add-on
controlled trials are currently ongoing with ziprasidone.
Aripiprazole
Aripiprazole is a partial agonist of dopamine D2/D3 and
serotonin (5-HT)1A receptors and an antagonist of 
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1705-HT2A and histamine H1 receptors, and a moderate
serotonin reuptake inhibitor.This agent demonstrated
a superior response rate to haloperidol (50% vs 28.4%)
in patients remaining on treatment in a 12-week com-
parative trial.
76
Two hundred and sixty-two patients with an acute manic
or mixed episode were randomized either to aripiprazole
or placebo.They were hospitalized at least for 2 weeks
and followed for an extra week.Aripiprazole significantly
improved YMRS scores (-8.2 vs -3.4 for placebo;P<0.01)
Response rate was significantly higher too (40% versus
19%; P<0.01) The percentage of aripiprazole-treated
patients achieving response was significantly higher than
that of placebo-treated patients as early as day 4 (14% vs
5%; P<0.05) This was confirmed by a second 3-week
study.Akathisia was significantly higher with aripiprazole
when compared with placebo.
77,78
Another trial randomized manic patients to aripiprazole
(n=175) or haloperidol (n=172).After 12 weeks,50.9%
of aripiprazole-treated patients and 29.1% of the
haloperidol group responded to treatment.Greater tol-
erability for aripiprazole should be considered when dis-
cussing these data,
51 because the definition of response
included the capacity to stay in the trial until its end.
There is only one very recent placebo-controlled trial
with aripiprazole as adjunctive treatment of mood stabi-
lizers,which showed better efficacy for the combination.
79
Activation and akathisia have been reported with arip-
iprazole.
Amisulpride
Only one controlled trial is available for this drug in
mania.A multicenter,open,randomized trial compared
amisulpride with haloperidol in manic patients taking
valproate.
80Amisulpride was not significantly superior to
haloperidol,but was better tolerated.In Spain,an open,
prospective, 6-week study was carried out with 20
patients with an acute manic episode (YMRS score of 20
or more) YMRS, the Hamilton Rating Scale for
Depression (HAM-D),the Clinical Global Impressions
Scale for Bipolar Disorder,Modified (CGI-BP-M) and
the systematic report of adverse events were used to
evaluate results. No other antipsychotics were used.
Seventy percent completed the study.Amisulpride sig-
nificantly improved the YMRS (P=0.0001),the HAM-D
(P<0.0141) and the overall (P=0.0003),mania (P=0.0001)
and depression (P=0.0268) subscales of the CGI-BP-M.
Researchers conclude that despite design limitations
(open,observational,small size) their prospective study
suggests that amisulpride could be an effective and rea-
sonably safe treatment for acute mania.
80 Amisulpride
may carry some risk of extrapyramidal side effects and
hyperprolactinemia.
Zotepine
A group from Germany has recently reported an open
study with zotepine.
81 Zotepine blocks D1,D 2,5-HT1,and
5-HT2 receptors.It behaves as a noradrenaline reuptake
inhibitor and antagonizes muscarine acetylcholine
(mAch) and H1 receptors,being sedative.Thus,its profile
is that of an atypical antipsychotic.Twelve patients with
severe manic episodes (mean YMRS 45+-7) and previ-
ous diagnosis of bipolar or schizoaffective disorder were
included and received zotepine as monotherapy. Ten
patients finished the study.Nine of them responded (50%
reduction in YMRS),5 of them within 4 days.One was
an inadequate responder.Response is described by the
authors as rapid.Four patients had extrapyramidal symp-
toms as a side effect. Unfortunately, there are no con-
trolled studies of zotepine as yet.
Asenapine
Asenapine is not yet available for clinical use,but it has
been tried in two placebo-controlled trials with overall
positive results.
82A further advantage is that it does not
seem to cause as much weight gain as other antipsy-
chotics,such as olanzapine.
83
Paliperidone
Placebo-controlled trials with paliperidone are currently
underway.As the active metabolite of risperidone,there
is no reason to expect anything but antimanic efficacy,
and a similar side-effect profile, but until the trials are
finalized,little else can be said.
Summary
A summary of the current evidence available for the
treatment of mania can be found in Table II (monother-
apy) and Table III (combination).Obviously,there are
still many gaps between the evidence from clinical trials
and the use of drugs in clinical practice.
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Nonpharmacological treatment 
of acute mania
Electroconvulsive therapy remains an effective option for
treatment-resistant mania and mixed states.
9,10 Much less evi-
dence,and in particular much less experience,is available for
other techniques,such as transcranial magnetic stimulation.
Psychotherapy is hard to provide during manic episodes,
and there is no evidence that it may actually help;rather
the opposite,Scott et al
84 have shown that psychosocial
interventions are more likely to work in patients who are
in remission or minimally symptomatic.Of course,some
common-sense-based,elementary educational informa-
tion can and should be provided during mania,and there
might be some room for more sophisticated interventions
in hypomania,
85 but the key message is that mania should
be treated with pharmacotherapy,whereas relapse pre-
vention can be an achievable goal with the combination
of drug therapy and psychotherapy.
Pharmacological long-term 
treatment of mania
The long-term treatment of mania is indeed the long-
term treatment of bipolar disorder, because not only
mania, but depression, are relevant outcomes.There is
far much more evidence for the long-term treatment of
patients with mania as index episode than for depres-
sion, though. Maintenance medication is generally rec-
ommended following a single acute manic episode, in
view of the 95% lifetime risk of recurrence.Maintenance
treatment is also appropriate in patients who experience
a breakthrough episode during the first year of treat-
Table II. Evidence base for the efficacy of drugs used to treat mania. Strength of evidence base (regardless of antimanic potency): +++, strong evi-
dence (positive large placebo-controlled trials); ++, some evidence (from secondary outcomes of placebo-controlled trials or other ran-
domized clinical trials); +, limited evidence (some evidence from small controlled studies or indirect evidence from clinical trials): ?, no evi-
dence available other than open studies; -, evidence of lack of efficacy from controlled trials.
Drug Acute mania Mixed mania Prevention of mania after mania Prevention of depression after mania
Lithium +++ + +++ ++
Valproate +++ ++ + ++
Carbamazepine +++ ++ + +
Lamotrigine - - + +++
Gabapentin - - ? ?
Topiramate - ? ? ?
Oxcarbazepine + + + ?
Licarbazepine - - ? ?
Chlorpromazine ++ + ? ?
Haloperidol +++ ++ ? ?
Clozapine + + ? ?
Risperidone +++ + + ?
Olanzapine +++ ++ +++ ++
Quetiapine +++ + +++ +++
Ziprasidone +++ ++ ? ?
Aripiprazole +++ ++ +++ ?
Asenapine +++ + ? ?
Drugs Lithium Valproate Carbamazepine Lamotrigine
Chlorpromazine ? ? ? ?
Haloperidol + + ? ?
Clozapine ? ? ? ?
Risperidone + + - ?
Olanzapine + + - ?
Quetiapine + + ? ?
Ziprasidone - - ? ?
Aripiprazole + + ? ?
Asenapine ? ? ? ?
Table III. Evidence base for combinations of antipsychotics with lithium
or anticonvulsants. Evidence base: +, positive in at least one
placebo-controlled trial; ?, no evidence available from clinical
trials; -, negative results in clinical trials so farAcute and long-term treatment of mania - Vieta and Sanchez-Moreno Dialogues in Clinical Neuroscience - Vol 10 . No.2 . 2008
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ment following an acute episode, and in chronically ill
patients with a long cycle length who do not achieve suf-
ficient remission of acute symptoms to be classified as
“recovered.”
Lithium
The prophylactic efficacy of lithium in bipolar I disorder
has been reported for several decades,and was recently
confirmed in a Cochrane review
86 and two meta-analy-
ses.
87,88At optimal dosing,lithium reduces recurrences by
around 50%, and appears to be more effective against
manic than depressive relapses.
89,90 Moreover, lithium
may have antisuicidal effects,independently of its effi-
cacy in preventing recurrences.
19,20,91 However,the efficacy
of lithium in clinical practice may be less than that in con-
trolled clinical trials,in part due to comorbidity and poor
adherence.Therefore,putative predictors of a favorable
response to lithium (eg,family history of bipolar disor-
der,no rapid cycling,complete interepisode recovery,no
substance abuse,good adherence) should be also be con-
sidered.
92 Indeed,the increased risk of relapse after sud-
den discontinuation of lithium,and potential for a lack
of response when lithium is reintroduced,have led some
experts to advise against using lithium in patients judged
unwilling or unlikely to adhere to treatment for at least
2 years.
18
Anticonvulsants
Valproate
Despite high expectations for the prophylactic efficacy
of valproate,the agent failed to demonstrate superiority
over placebo in preventing recurrence of bipolar
episodes in a randomized controlled trial.
93 However,sec-
ondary analyses indicated that valproate was superior to
placebo in severely ill patients and was effective in pre-
venting new depressive episodes.In randomized studies
with active comparators, valproate was equivalent to
lithium
94,95 and olanzapine
96 in the prevention of bipolar
recurrence.Valproate has controversially been reported
to induce polycystic ovary syndrome.
Carbamazepine
Carbamazepine is a widely used in patients who have not
responded to treatment with lithium,especially in Europe
and Japan.It has been shown to be superior to placebo in
a small trial,
97 and was equal to lithium in meta-analysis.
98
However, the studies were too heterogeneous to allow
conclusive results. In a 2.5-year randomized study of
lithium and carbamazepine,lithium was associated with a
lower overall rate of relapse (28% vs 47%) and fewer
adverse events.
99 However,carbamazepine appeared more
effective than lithium in patients with atypical features
such as mixed states and delusions,
100 suggesting it has a
broader spectrum of activity.A study of treatment-naïve
bipolar patients showed that lithium was slightly more
effective than carbamazepine in preventing relapses over
a 2-year period,although carbamazepine was superior dur-
ing the first 6 months.
101
Other anticonvulsants
The evidence supporting lamotrigine prophylaxis is
strong,particularly where preventing depressive episodes
is a major objective, but clearly not as much as far as
mania is concerned.Lamotrigine as maintenance therapy
has been studied in two large randomized, controlled
studies in bipolar patients with a recent depressive
89 or
manic/hypomanic episode.
90These studies showed that
lamotrigine was superior to placebo in preventing
depressive episodes and in delaying the onset of any
mood episode.Furthermore,in a pooled analysis,lamot-
rigine was significantly better than placebo in preventing
manic, hypomanic, or mixed episodes.
102 Limited con-
trolled data are available on the long-term outcome of
bipolar patients treated with oxcarbazepine.
41,103A small
study suggested that phenytoin might have some mood-
stabilizing properties,
104 and another pilot,randomized,
placebo-controlled trial,suggested that gabapentin might
have some prophylactic effects when used in conjunction
with lithium in euthymic patients with a highly recurring
course.
105
Antipsychotics
Long-term treatment with low doses of antipsychotics is
not a rare practice in clinical settings when treating bipo-
lar patients.
106As the first-generation antipsychotics are
not effective in preventing depressive phases and could
be involved in depressive relapses,
107 they do not seem an
interesting option for maintenance. However, there is
growing evidence of second-generation antipsychotics
having mood-stabilizing properties.
6Clozapine
Hummel et al published a series of 3 cases (2 with bipo-
lar disorder, 1 with schizoaffective disorder) in which
mood stabilizer had been enhanced with clozapine.All
of them were revisited monthly for at least 6 months
before and after the addition of clozapine.Response was
evaluated using the Inventory of Depressive
Symptomatology (IDS),YMRS,Global Assessment of
Functioning (GAF),CGI-BP,and the NIMH Life Chart
Methodology, which showed improvement in all cases
after clozapine was added.Weight gain and fatigue were
the most common reported side effects.
108
A randomized study included 38 treatment-resistant
patients with schizoaffective disorder,bipolar type,and
bipolar I disorder. Two groups were randomly set: 19
would receive clozapine as add-on treatment whilst 19
would be treated as usual (no clozapine was received).
Both groups were followed up for 1 year.Different scales
noted a significantly greater improvement in the clozap-
ine group than in the patients not receiving clozapine.
109
Atypical antipsychotics might reduce rates of emergency
room visits as a group,but the effect is probably greater
in the case of clozapine.
110As mentioned earlier,the prob-
lems with long-term clozapine are more weight gain and
metabolic issues,rather than agranulocytosis.
Risperidone
No controlled trials are available with risperidone
beyond 12 weeks,but in 2001 a large open study in 541
bipolar and schizoaffective bipolar patients was reported
on. Its goal was to study whether risperidone was an
effective and safe adjunction to mood stabilizers.Patients
were followed for 6 months in this multicenter study.At
their entry they were experiencing manic, hypomanic,
mixed,or depressive episodes.After addition of risperi-
done, significant improvements on YMRS, HAM-D,
CGI,and PANSS were noted (P<0.0001).The mean dose
of risperidone was 3.9 mg/day.No new-emergent tardive
dyskinesia cases were identified,and mania exacerbation
within the first 6 weeks was as low as 1.8%.Although
extrapyramidal symptoms and weight gain were the most
common side effects reported, and were not very fre-
quent,the authors concluded that risperidone was effec-
tive and safe when combined with mood stabilizers in the
treatment of bipolar disorder and schizoaffective bipolar
disorder.
61 Similar conclusions were obtained in another
observational study by Yatham et al.
111The same authors
compared risperidone added to either lithium or val-
proate,finding that efficacy and safety were not related
to the adjunctive mood stabilizer.
112The main issues with
long-term risperidone therapy are those related with
hyperprolactinamia. Trials with injectable long-acting
risperidone are currently underway,but a recent open,
mirror-design study suggests that it may be helpful to
prevent hospitalizations due to mania and to improve
treatment adherence.
113
Olanzapine
Olanzapine has been widely studied and is approved by
the FDA and the European Medicaments Agency
(EMEA) for maintenance treatment.Several trials sup-
port its use in the maintenance phase of bipolar disorder,
not only as adjunctive therapy with mood stabilizers,but
also as monotherapy after successful treatment of mania.
A 12-month placebo-controlled olanzapine monother-
apy trial demonstrated that olanzapine was significantly
superior to placebo in preventing any mood episode,
including manic,depressive,and mixed recurrences.
68
In a 47-week double-blind trial, 251 bipolar patients,
through a manic or mixed episode,were randomized to
olanzapine (n=125) or divalproex (n=126) Efficacy was
rated with the YMRS (at least 20 for inclusion, lower
than 12 for remission,and higher than 15 for relapse) At
end point the olanzapine group achieved significantly
greater mean improvement in YMRS.Nevertheless,no
difference was noted in rates of bipolar relapse between
both treatments.Some olanzapine-treated patients pre-
sented somnolence,dry mouth,increased appetite,weight
gain,akathisia,and high alanine aminotransferase levels,
while nausea and nervousness were reported by the
divalproex-treated patients.
96
Olanzapine was compared with lithium in a double-blind
trial comprising 431 patients.After 52 weeks,olanzapine
was similar to lithium in preventing depressive episodes,
but superior in preventing manic or mixed relapses.
114This
study suggested olanzapine’s efficacy in relapse preven-
tion,which was tested in a double-blind placebo-controlled
12-month clinical trial. Patients with an acute manic or
mixed episode received olanzapine for 6-12 weeks.Those
who remitted were randomized to olanzapine (n=225) or
placebo (n=136) and joined a double-blind 52-week trial.
Olanzapine was superior to placebo in preventing any
kind of bipolar relapse (46.7% vs 80.1%; P<0.001) and
174
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relapse into a manic episode (16.4% vs 41.2%;P<0.001)
or a depressive episode (34.7% vs 47.8%,P=0.015).Side
effects were more prominent in the olanzapine-treated
group (weight gain, fatigue, and akathisia) than in the
placebo group. More patients finished the study in the
olanzapine group.
114
Efficacy of olanzapine combined with a mood stabilizer
in prevention of bipolar relapses was studied in an 18-
month double-blind study.At the starting point,patients
scored at least 16 on the YMRS.Fifty-one were random-
ized to olanzapine and 48 to placebo. Both groups
received lithium or valproate semisodium.Median time
to bipolar symptomatic relapse was significantly higher
in the olanzapine-mood stabilizer group (163 vs 42 days;
P=0.023),but there were no differences in time to bipo-
lar syndromic relapse (94 vs 40.5 days;P=0.742).
115
Olanzapine is one of the best-studied second-generation
antipsychotics in bipolar disorder.The main downside for
its use in maintenance is its propensity to induce weight
gain and the risk of metabolic syndrome.
63
Quetiapine
After some preliminary evidence from open, non-con-
trolled trials,
116 controlled trials of quetiapine in mainte-
nance have just been finalized,showing for the first time
a positive outcome with regard to prevention of manic and
depressive recurrences from either manic, mixed, or
depressive index episode in a 2-year placebo-controlled
add-on study.
117 Importantly,patients were enrolled while
manic,depressed,or mixed,and were required to be stable
for at least 12 weeks before randomization.The main short-
comings of quetiapine in this indication are persistent seda-
tion and weight gain,which is significantly lower than with
clozapine or olanzapine,but still relevant,and also some
signal of glucose increase.These issues can sometimes be
partially addressed by adjusting the dose downwards.
Ziprasidone
There are no controlled long-term trials with ziprasidone
in bipolar disorder to date.The open extension phase of
some of the acute trials suggests that it could be helpful
as augmentation therapy in a relatively well-tolerated
way,but this should be confirmed in future controlled tri-
als,
118 which might confirm its potential effectiveness and
low propensity to cause weight gain,in contrast with the
majority of antipsychotics.
Aripiprazole
Aripiprazole is approved by the FDA for maintenance
treatment.To date there is only one relapse prevention
study with aripiprazole. A 26-week double-blind trial
admitted euthymic patients (YMRS not higher than 10
and Montgomery-Asberg Depression Rating Scale
(MADRS) not higher than 13 during four visits or 6
weeks) and randomized them to aripiprazole (n=78) or
placebo (n=83). The aripiprazole group had a signifi-
cantly lower percentage of manic relapses,but there were
no statistical differences in depressive relapses between
groups.
119
Amisulpride
Only one,methodologically limited study is available so
far in bipolar maintenance with this compound. Carta
and coworkers
120 reported positive outcomes using
amisulpride as adjunctive long-term pharmacotherapy in
14 bipolar I patients.
Nonpharmacological long-term treatment
Electroconvulsive therapy
The use of maintenance electroconvulsive therapy 
is more supported by anecdotal experience than by 
scientific evidence, but has been reported as a 
useful and safe strategy for treatment-resistant
patients.
121,122
Psychoeducation
Interventions based on intensive education for patients
or relatives have proved to be useful for the prevention
of further episodes,
123-126 but mostly if applied when the
patient is not acutely ill.
84 The evidence for pure cogni-
tive-behavioral interventions is controversial,
127-129 as
well as for interpersonal and social rhythm therapy,
130,131
and practically absent for other types of interventions,
such as psychoanalytical therapy.The active ingredients
of the effective therapies seem to be those related to
enhanced medication adherence,illness awareness and
skills for the detection of prodromal signs of relapse,
avoidance of drug misuse, stabilitzation of sleep and
other rhythms, and coping strategies when faced with
stress.
132Conclusions
In summary, the treatment of mania still poses very
important challenges,particularly as far as the long term
is concerned.In the last decade,a number of new drugs
have proved to be effective and have increased our treat-
ment armamentarium for this condition, resulting in
more compounds receiving an indication in the treatment
of acute mania and maintenance treatment.Currently,
lithium, valproate, carbamazepine, chlorpromazine,
haloperidol,risperidone,olanzapine,quetiapine,ziprasi-
done,and aripiprazole are indicated for the treatment of
acute mania in the majority of European countries and
North America,with some minor variations from coun-
try to country,and lithium,valproate,lamotrigine,olan-
zapine, aripiprazole, and quetiapine are indicated for
maintenance treatment,again depending on the country.
However, the gap between evidence base and clinical
practice is still huge,and the majority of patients have to
be treated with combinations of several drugs and psy-
chosocial interventions in order to achieve a reasonable
outcome from the clinical as well as functional point of
view. This may be particularly true for patients with
rapid-cycling bipolar disorder,who may need complex
combinations of therapies and sometimes physical treat-
ments such as electroconvulsive therapy to achieve clin-
ical stability.For these patients,as well as for those with
mixed states, for those with enduring subsyndromal
symptoms,and ultimately for the majority of people with
bipolar disorder,more efficacious,tolerable treatments
are badly needed. ❏
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Tratiamento a corto y lungo plazo de la
mania
El tratamiento de la manía comienza con un diag-
nóstico correcto y medidas elementales para preve-
nir riesgos para el paciente, familiares, y terceras per-
sonas. En ocasiones, el ingreso y tratamiento
involuntarios son necesarios durante algunos días.
Los pacientes con manía psicótica o mixta pueden ser
más difíciles de tratar. Actualmente existen pruebas
solidas de la eficacia del litio, los antiepilépticos val-
proato y carbamazepina, y los antipsicoticos clor-
promacina, haloperidol, risperidona, olanzapina,
quetiapina, ziprasidona, aripiprazol, y asenapina en
la mania aguda, y también indicios de la eficacia de
la clozapina y de la terapia electroconvulsiva en casos
resistentes al tratamiento. Sin embargo, en la prác-
tica clínica, el tratamiento combinado es la norma
más que la excepción. El tratamiento de la manía
requiere una visión a largo plazo, y los fundamentos
científicos podrían ser mas sólidos para unos com-
puestos que otros. A la hora de tomar decisiones res-
pecto al tratamiento, la tolerabilidad debería ser una
cuestión fundamental, ya que las diferencias en
seguridad y tolerabilidad pueden ser mayores que
las de eficacia entre fármacos. La psicoeducación de
pacientes y familiares es una herramienta poderosa
que debería combinarse con el tratamiento farma-
cológico para un mejor pronóstico a largo plazo. La
recuperación funcional debería ser la meta final.
Traitement aigu et à long terme de l’état
maniaque
Le traitement de l’état maniaque débute par un dia-
gnostic adéquat et des mesures élémentaires pour
éviter de mettre en péril le patient, ses proches et
autrui. Il faut parfois imposer une hospitalisation et
un traitement pendant quelques jours, car les
patients psychotiques ou maniaques mixtes peuvent
être plus difficiles à traiter. À l’heure actuelle, des
arguments sérieux sont en faveur de l’utilisation du
lithium, des anticonvulsivants comme le valproate et
la carbamazépine, et des antipsychotiques comme la
chlorpromazine, l’halopéridol, la rispéridone, l’olan-
zapine, la quétiapine, la ziprasidone, l’aripiprazole et
l’asénapine au cours de l’état maniaque aigu.
D’autres observations mettent en avant l’utilisation
de la clozapine ou des électrochocs dans les cas réfrac-
taires au traitement. Cependant, en pratique clinique,
l’association de plusieurs traitements est la règle plu-
tôt que l’exception. Le traitement de l’état maniaque
mérite une vision à long terme, et les fondements de
certains traitements peuvent être plus forts que
d’autres. Lorsque la décision du traitement est prise,
il faut aussi prendre en compte la tolérance, car des
différences d’innocuité et de tolérance peuvent sup-
planter des différences d’efficacité pour la plupart des
produits. L’éducation psychologique des patients et
des soignants est un outil puissant qui devrait être uti-
lisé en association avec le traitement pour des résul-
tats optimaux à long terme. La guérison fonctionnelle
du patient devrait être l’objectif final. 45. Cookson J, Silverstone T, Wells B. Double-blind comparative clinical trial
of pimozide and chlorpromazine in mania. A test of the dopamine hypoth-
esis. Acta Psychiatr Scand. 1981;64:381-397.
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